APPLICANT FACSIMILE OF FORM PTO-1449 (Rev. 2-80)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY DOCKET NO	SERIAL NO.
		RPI-011CPCN	09/995519
LIST OF PUBLICATIONS CITED BY APPLICANT (Use several sheets if necessary)		APPLICANT: Boussiotis, V.A., *et al.*	
		FILING DATE: November 28, 2001	GROUP: 1644

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	AA	5,116,964	5/26/92	Capon et al	536	27	
	AB	5,434,131	7/18/95	Linsley et al.	514	2	

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES	TRANSLATION NO
	AC	WO 90/05541	5/31/90	PCT				
	AD	WO 91/11194	8/8/91	PCT				
	AE	WO 92/00092	1/9/92	PCT				
	AF	WO 92/15671	9/17/92	PCT				
	AG	0503646 A1	12/3/92	EPO				
	AH	WO 93/00431	1/7/93	PCT				
	AI	WO 93/06852	4/15/93	PCT				
	AJ	WO 93/06866	4/15/93	PCT				

OTHERS (including Author, Title, Date, Pertinent Pages, Etc.)

	AK	Azuma, M., et al., "B70 Antigen is a Second Ligand for CTLA-4 and CD28," *Nature*, vol. 366, 76-79 (1993);
	AL	Bell, G. and Imboden, J., "CD2 and the Regulation of T Cell Anergy," *The Journal of Immunology*, 2805-2807 (1995);
	AM	Beverly, B., et al., "Reversal of in Vitro T Cell Clonal Anergy by IL-2 Stimulation," *International Immunology*, vol. 4, no. 6, 661-671 (1992);
	AN	Bierer, B., et al., "Interaction of CD2 with its Ligand, LFA-3, in Human T Cell Proliferation," *The Journal of Immunology*, vol. 140, no. 10, 3358-3363 (1988);
	AO	Bierer, B., et al., "Synergistic T Cell Activation Via the Physiological Ligands for CD2 and the T Cell Receptor," *J. Exp. Med.*, vol. 168, 1145-1156 (1988);
	AP	Boussiotis, V., et al., "B7 but not Intercellular Adhesion Molecule-1 Costimulation Prevents the Induction of Human Alloantigen-specific Tolerance," *J. Exp. Med.*, vol. 178, 1753-1763 (1993);
	AQ	Boussiotis, V., et al., "CD2 is Involved in Maintenance and Reversal of Human Alloantigen-specific Clonal Anergy," *J. Exp. Med.*, vol. 180, 1665-1673 (1994);
	AR	Boussiotis, V., et al., "Human Alloantigen Specific Clonal Anergy to Lymphoblastoid Cells is Reversed Following Culture with IL-2 or IL-4," *Blood*, vol. 82, 304A (1993);
	AS	Brottier, P., et al., "T Cell Activation Via CD2 [T, gp50] Molecules: Accessory Cells are Required to Trigger T Cell Activation Via CD2-D66 Plus CD2-9.6/T11, Epitopes," *The Journal of Immunology*, vol. 135, no. 3, 1624-1631 (1985);

Examiner	Date Considered
PHUONG GAMBEL	4/11/05

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

		09/995519
	FILING DATE November 28, 2001	GROUP 1644

OTHERS (including Author, Title, Date, Pertinent Pages, Etc.)

	BA		Dustin, M., et al., "Anchoring Mechanisms for LFA-3 Cell Adhesion Glycoprotein at Membrane Surface," *Nature*, vol. 329, 846-848 (1987);
	BB		Freedman, A., et al., "B7, a B Cell-Restricted Antigen that Identifies Preactivated B Cells," Division of Tumor Immunology, Dana-Farber Cancer Institute and the Department of Medicine, 3260-3267 (1987);
	BC		Freeman, G., et al., "B7, a new Member of the Ig Superfamily with Unique Expression on Activated and Neoplastic B Cells," *The Journal of Immunology*, vol. 143, no. 8, 2714-2722 (1989);
	BD		Freeman, G., et al., "Cloning of B7-2: A CTLA-4 Counter-Receptor that Costimulates Human T Cell Proliferation," *Science*, vol. 262, 909-911 (1993);
	BE		Freeman, G., et al., "Murine B7-2, an Alternative CTLA4 Counter-receptor that Costimulates T Cell Proliferation and Interleukin 2 Production," *The Journal of Experimental Medicine*, vol. 178, 2185-2192 (1993);
	BF		Freeman, G., et al., "Structure, Expression, and T Cell Costimulatory Activity of the Murine Homologue of the Human B Lymphocyte Activation Antigen B7," *J. Exp. Med.*, vol. 174, 625-631 (1991);
	BG		Freeman, G., et al., "Uncovering of Functional Alternative CTLA-4 Counter-Receptor in B7-Deficient Mice," *Science*, vol. 262, 907-909 (1993);
	BH		Gimmi, C., et al., "B-cell Surface Antigen B7 Provides a Costimulatory Signal that Induces T Cells to Proliferate and Secrete Interleukin 2," *Proc. Natl. Acad. Sci. USA*, vol. 88, 6575-6579 (1991);
	BI		Gimmi, C., et al., "Human T-cell Clonal Anergy is Induced by Antigen Presentation in the Absence of B7 Costimulation," *Proc. Natl. Acad. Sci. USA*, vol. 90, 6586-6590 (1993);
	BJ		Harding, F., et al., "CD28-mediated Signaling Co-stimulates Murine T Cells and Prevents Induction of Anergy in T-cell Clones," *Nature*, vol. 356, 607-609 (1992);
	BK		Hathcock, K., et al., "Identification of an Alternative CTLA-4 Ligand Costimulatory for T Cell Activation," *Science*, vol. 262, 905-907 (1993);
	BL		Koyasu, S., et al., "Role of Interaction of CD2 Molecules with Lymphocyte Function-associated Antigen 3 in T-cell Recognition of Nominal Antigen," *Proc. Natl. Acad. Sci. USA*, vol. 87, 2603-2607 (1990);
	BM		Lenschow, D., et al., "Long-Term Survival of Xenogeneic Pancreatic Islet Grafts Induced by CTLA4Ig," *Science*, vol. 257, 789-791 (1992);
	BN		Lin, H., et al., "Long-Term Acceptance of Major Histocompatibility Complex Mismatched Cardiac Allografts Induced by CTLA4Ig Plus Donor-specific Transfusion," *J. Exp. Med.*, vol.178, 1801-1806 (1993);
	BO		Linsley, P., et al., "Binding of the B Cell Activation Antigen B7 to CD28 Costimulates T Cell Proliferation and Interleukin 2 mRNA Accumulation," *J. Exp. Med.*, vol. 173, 721-730 (1991);
	BP		Linsley, P., et al., "Immunosuppression in Vivo by a Soluble Form of the CTLA-4 T Cell Activation Molecule," *Science*, vol. 257, 792-795 (1992);
	BQ		Meuer, S., et al., "An Alternative Pathway of T-Cell Activation: A Functional Role for the 50 kd T11 Sheep Erythrocyte Receptor Protein," *Cell*, vol. 36, 897-906 (1984);
	BR		Moingeon, P., et al., "CD2-mediated Adhesion Facilitates T Lymphocyte Antigen Recognition Function," *Nature*, vol. 339, 312-314 (1989);

Examiner	PHILIP GAMBEL	Date Considered	4/11/05

*EXAMINER			Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

PATENT & TRADEMARK LIST OF PUBLICATIONS CITED BY APPLICANT (Use several sheets if necessary)	09/995519	
	APPLICANT: Boussiotis, V.A., *et al.*	
	FILING DATE: November 28, 2001	GROUP: 1644

OTHERS (including Author, Title, Date, Pertinent Pages, Etc.)

	CA		Pepinsky, R., et al., "The Increased Potency of Cross-linked Lymphocyte Function-associated Antigen-3 (LFA-3) Multimers is a Direct Consequence of Changes in Valency," *The Journal of Biological Chemistry*, vol. 266, no. 27, 18244-18249 (1991);
	CB		Seed, B., "An LFA-3 cDNA Encodes a Phospholipid-linked Membrane Protein Homologous to its Receptor CD2," *Nature*, vol. 329, 840-842 (1987);
	CC		Selvaraj, P., et al., "The T Lymphocyte Glycoprotein CD2 Binds the Cell Surface Ligand LFA-3," *Nature*, vol. 326, 400-403 (1987);
	CD		Tan, P., et al., "Induction of Alloantigen-specific Hyporesponsiveness in Human T Lymphocytes by Blocking Interaction of CD28 with its Natural Ligand B7/BB1," *J. Exp. Med.*, vol. 177, 165-173 (1993);
	CE		Van Gool, S., et al., "The Combination of Anti-B7 Monoclonal Antibody and Cyclosporin A Induces Alloantigen-specific Anergy During a Primary Mixed Lymphocyte Reaction," *J. Exp. Med.*, vol. 179, 715-720 (1994);
	CF		Wallner, B., et al., "Primary Structure of Lymphocyte Function-Associated Antigen 3 (LFA-3) The Ligand of the T Lymphocyte CD2 Glycoprotein," *Journal of Experimental Medicine*, vol. 166, 923-932 (1987);
	CG		Yang, S., et al., "A Common Pathway for T Lymphocyte Activation Involving Both the CD3-Ti Complex and CD2 Sheep Erythrocyte Receptor Determinants," *The Journal of Immunology*, vol. 137, no. 4, 1097-1100 (1986).
	CH		
	CI		
	CJ		
	CK		
	CL		
	CM		
	CN		
	CO		
	CP		
	CQ		
	CR		
	CS		

Examiner		Date Considered	4/11/05
*EXAMINER			Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.